IRIS
FASANO, MASSIMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.716
NA - Nord America 1.980
AS - Asia 1.584
Continente sconosciuto - Info sul continente non disponibili 21
SA - Sud America 11
AF - Africa 6
OC - Oceania 4
Totale 6.322
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.974
CN - Cina 995
IE - Irlanda 929
UA - Ucraina 709
SE - Svezia 479
FR - Francia 203
IN - India 202
TR - Turchia 178
FI - Finlandia 167
VN - Vietnam 118
IT - Italia 76
SG - Singapore 65
GB - Regno Unito 54
DE - Germania 50
EU - Europa 21
CZ - Repubblica Ceca 13
AT - Austria 9
BE - Belgio 8
SY - Repubblica araba siriana 7
UY - Uruguay 7
PK - Pakistan 6
RU - Federazione Russa 6
CA - Canada 4
EG - Egitto 4
BG - Bulgaria 3
CH - Svizzera 3
ES - Italia 3
AR - Argentina 2
AU - Australia 2
HK - Hong Kong 2
IR - Iran 2
KR - Corea 2
MX - Messico 2
MY - Malesia 2
NL - Olanda 2
NZ - Nuova Zelanda 2
SA - Arabia Saudita 2
AE - Emirati Arabi Uniti 1
CL - Cile 1
GH - Ghana 1
GR - Grecia 1
IQ - Iraq 1
ML - Mali 1
PE - Perù 1
RS - Serbia 1
TH - Thailandia 1
Totale 6.322
Salva come PNG Salva come JPEG
Città #
Dublin 927
Jacksonville 505
Dearborn 317
Nyköping 298
Nanjing 281
Chandler 249
Wilmington 137
Dong Ket 117
Beijing 104
Nanchang 102
Princeton 102
San Mateo 79
Helsinki 73
Shenyang 60
Hebei 52
Kunming 51
Tianjin 44
Ashburn 39
Jiaxing 37
Ann Arbor 35
Changsha 34
Singapore 30
Ningbo 29
Jinan 26
Stevenage 24
Des Moines 23
Zhengzhou 21
Guangzhou 19
Hilden 19
Hangzhou 17
Lanzhou 15
Shanghai 15
Brno 13
Taizhou 13
Redwood City 12
London 11
New York 11
Munich 9
Pune 9
Vienna 9
Woodbridge 9
Ankara 8
Chengdu 8
Foggia 8
Montevideo 7
Orange 7
San Jose 7
Boardman 6
Brussels 6
Hefei 6
Norwalk 6
Bari 5
Changchun 5
Los Angeles 5
Al Mansurah 4
Augusta 4
Chicago 4
Fairfield 4
Leawood 4
Wuhan 4
Zhangzhou 4
Borås 3
Fuzhou 3
Gurgaon 3
Istanbul 3
Jinhua 3
Rockville 3
Saint Petersburg 3
Central 2
Elche 2
Gunzenhausen 2
Hanover 2
Kraainem 2
Modena 2
Oxford 2
Palo del Colle 2
Paris 2
Pennington 2
Perm 2
Pesaro 2
Priverno 2
Redmond 2
Rome 2
Santa Clara 2
Shaoxing 2
Xuzhou 2
Acquaviva Delle Fonti 1
Anqing 1
Athens 1
Auckland 1
Balıkesir 1
Baotou 1
Bethesda 1
Brindisi 1
Brooklyn 1
Cedar Knolls 1
Chongqing 1
Christchurch 1
Dammam 1
Dubai 1
Totale 4.160
Salva come PNG Salva come JPEG
Nome #
2-years effectiveness and safety of tenofovir in 302 NUC-naïve patients with chronic hepatitis B: a multicenter European study in clinical practice 155
2-years effectiveness and safety of tenofovir in 302 NUC-naïve patients with chronic hepatitis B: a multicenter European study in clinical practice 126
2-YEAR EFFECTIVENESS AND SAFETY OF TENOFOVIR IN 302 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICE 114
5-year Entecavir in NUC-naïve, field practice patients with CHB showed excellent viral suppression and safety but no prevention of HCC 107
Hepatitis C virus clearance after direct-acting antivirals in cirrhotic patients by stages of liver impairment: the ITAL-C network study 94
Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study. 92
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C. 92
Four years of tenofovir monotherapy for NUC naive field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis 90
Nucleios(t)ide analogue discontinuation is not associated with increased rates of HBsAg loss in chronic hepatitis B 90
EFFICACY AND SAFETY OF LONG-TERM THERAPY WITH ENTECAVIR (ETV) OR TENOFOVIR (TDF) IN PATIENTS WITH HBV-RELATED CIRRHOSIS 85
Flares during long-term entecavir therapy in chronic hepatitis B 85
5-YEAR ENTECAVIR TREATMENT IN NUC-NAIVE, FIELD-PRACTICE PATIENTS WITH CHRONIC HEPATITIS B SHOWED EXCELLENT VIRAL SUPPRESSION AND SAFETY PROFILE BUT NO PREVENTION OF HCC IN CIRRHOTICS 82
Acute Hepatitis C in Haemodialysis patients: natural course and response to IFNα-monotherapy 78
Entecavir monotherapy improves renal function in patients developing renal side effects during long-term tenofovir treatment without compromising virological response: a multicenter real-life study in 103 patients 78
Patients with HDV infection and advanced fibrosis/cirrhosis present a high but predictable risk of developing hepatocellular carcinoma 77
Tenofovir suppressed viral suppression in most field practice, treatment-naive patients with CHB followed for 3 years in a multicenter European study 75
preliminary Data From the Study of Coagulative Profile of HIV infected Individuals suggest a role for point mutations in the Gene in protein S deficiency in Individuals undergoing Higly Antiretroviral therapy 74
Efficacia e tollerabilità della monoterapia con Entecavir (ETV) in pazienti con epatite cronica B 73
THE ITALIAN ENTAS COHORT STUDY: ENTECAVIR EFFECTIVENESS IN NAïVE AND TREATMENT EXPERIENCED PATIENTS WITH CHRONIC HEPATITIS B 73
ENTECAVIR MONOTHERAPY IN 418 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B FROM FIELD PRACTICE: HIGH EFFICACY AND FAVORABLE SAFETY PROFILE OVER 3 YEARS OF TREATMENT 73
Current Concepts on Management of Chronic Hepatitis BPractical Management of Chronic Viral Hepatitis 72
A MODEL TO PREDICT SUCCESS FOLLOWING PEG-INTERFERON AND RIBAVIRIN THERAPY FOR PATIENTS WITH HCV-1 INFECTION 72
An open, randomized, multicentre trial to evaluate efficacy and safety of a 24 week-course of Peg-interferon α-2b versus a 12 week-course of Peg-Interferon α-2b alone or plus ribavirin in patients with acute hepatitis C 71
Cost-effectiveness of Tenofovir in the treatment of patients with chronic hepatitis B: data from literature 71
Analisi di costo-efficacia del trattamento dell’epatite cronica B con analoghi nucleos(t)idici nella pratica clinica 70
.Long-term lamivudine treatment in patients with HBeAg negative chronic hepatitis B: how long? 70
Malattie causate da Elminti 70
Nuove strategie di trattamento 70
Come trattare il paziente con non risposta o risposta virologica parziale 69
Acute hepatitis C: clinical and laboratory diagnosis, course of the disease, treatment. 69
Detection of in vivo hepatitis B virus surface antigen mutations-a comparison of four routine screening assays 69
Acute hepatitis C: A 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin 68
A proposito di epatite B. News da EASL 2008. 67
Definizione delle resistenze e metodiche di laboratorio 67
Chronic hepatitis B: Advances in treatment. 67
Risposta virologica e resistenza ad Adefovir dipivoxil (ADV) in pazienti con Epatite Cronica B resistente alla Lamivudina (LAM) 66
Selection of HCV-1 patients with chronic hepatitis who might benefit from current standard of therapy with peg-interferon and ribavirin 66
Entecavir monotherapy in 418 NUC-naïve patients with chronic hepatitis B from field practice: high efficacy and favourable safety profile over 3 years of treatment 65
Resistance profile of entecavir in patients with chronic hepatitis B 65
Risposta alla terapia con Adefovir Dipivoxil (ADV) in pazienti con Epatite Cronica B, resistenti alla Lamivudina 65
Interim analysis of the Italian Master-Entas cohort study: entecavir effectiveness in field practice for chronic hepatitis B 64
Entecavir effectiveness in naïve and NUC experienced patients: Interim analysis of the ENTAS cohort study of patients with chronic hepatitis B 64
Effectiveness of entecavir for NUC-naïve, HBeAg-negative chronic hepatitis B patients in clinical practice: a 2-year multicenter cohort study in 311 patients 64
Epatite acuta C a risoluzione spontanea: evoluzione a lungo termine 64
HBsAg loss is enough to discontinue long-term nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B patients in real practice 64
Long-term response to lamivudine monotherapy in patients with HBeAg-negative chronic hepatitis B: to change or not to change? 63
Tenofovir monotherapy suppressed viral suppression in most field practice, treatment-naive patients with chronic hepatitis B followed for 3 years in a multicenter European study 63
Epatite acuta C in un’ampia coorte di pazienti: fattori di rischio ed evoluzione 63
Diagnostic value of alpha-fetoprotein for early hepatocellular carcinoma diagnosis in cirrhotic HBV patient successfully treated with nucleos(t)ide analogues - a case report 63
Mutations selected during lamivudine therapy may predispose to adefovir resistance 62
Adefovir resistance patterns in patients with lamivudine resistant chronic hepatitis B 62
Dalla terapia di combinazione Lamivudina+Adefovir alla monoterapia con Tenofovir in pazienti con Epatite Cronica B, HBeAg-negativa: risultati di efficacia e sicurezza 62
Selection of HCV-1 patients with chronic hepatitis who might benefit from current standard of therapy with peg-interferon and ribavirin. 19th International Symposium on Hepatitis C Virus and Related Viruses 61
ENTECAVIR EFFECT ON LIVER FUNCTION IN FIELD PRACTICE: INTERIM ANALYSIS OF THE ITALIAN Master-Entas COHORT STUDY OF PATIENTS WITH CHRONIC HEPATITIS B 60
Entecavir treatment for NUC naïve, field practice patients with chronic hepatitis B: excellent viral suppression and safety profile over 5 years of treatment 60
Long-term follow up of patients with acute hepatitis C and spontaneous resolution 60
PREDICTION OF HBeAg SEROCONVERSION IN HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH ENTECAVIR USING ALT AND PLATELET COUNT: RESULTS FROM A LARGE EUROPEAN MULTI-CENTER STUDY 60
Risk of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogues and long-term virological suppression 60
Impact of adding raltegravir to antiretroviral regimens in patients with blood viral suppression but persistent seminal viral shedding 60
Epatite B e Immigrazione 59
Early hepatic flares during ETV treatment are rare and do not require treatment adaptation in chronic hepatitis B without cirrhosis 58
Effectiveness of entecavir in field practice: interim analysis of the Italian MASTER-ENTAS cohort study of patients with chronic hepatitis B 58
No beneficial of long-term analogue treatment on the clinical outcome of patients with chronic hepatitis Delta and advanced liver disease. A case-control study. 58
Genotypic resistance to adefovir (ADV) in patients with lamivudine (LAM) resistant chronic hepatitis B 56
Tenofovir monotherapy for naïve patients with chronic hepatitis B: a multicenter European study in clinical practice in 302 patients followed for 30 months 54
Entecavir for NUC-naïve chronic hepatitis B patients in clinical practice: long-term effectiveness from large multicenter cohort study in 376 patients 54
Maintained viral suppression and excellent safety profile of Entecavir monotherapy in 418 NUC-naïve patients with chronic hepatitis B: a 4-year field practice, multicenter study 54
Long-Term HDV-RNA Suppression – HBsAg Clearance in Chronic Hepatitis D Following Interferon Therapy 54
Risposta a lungo termine alla monoterapia con lamivudina in pazienti con epatite cronica B, HBeAg negativa: è opportuno cambiare? 54
Epatite acuta C in pazienti in trattamento emodialitico periodico. 54
Longitudinal PAGE-B Scores Predict the Risk of Hepatocellular Carcinoma and other Adverse Clinical Outcomes in Chronic Hepatitis B Patients on Entecavir Therapy 54
Interim analysis of the Italian Master-Entas cohort study: entecavir can improve liver function in patients with chronic hepatitis B and liver cirrhosis 53
An open, randomized, multicentre trial to evaluate efficacy and safety of a 24 week-course of Peg-Interferon α-2b versus a 12-week-course of Peg-Interferon α-2b alone or plus ribavirin in patients with Acute Hepatitis C 53
Entecavir monotherapy in 418 NUC-naïve patients with chronic hepatitis B from field practice: high efficacy and favourable safety profile over 3 years of treatment 53
HBV and immigrants: a SIMIT multicenter cross-sectional study 53
HBSAG LOSS IS ENOUGH TO DISCONTINUE LONG-TERM NUCLEOS(T)IDE ANALOGUE THERAPY IN HBEAG-NEGATIVE CHRONIC HEPATITIS B PATIENTS IN REAL PRACTICE? 53
Terapia a lungo termine con Lamivudina in pazienti con epatite cronica B anti-HBe positiva: quando sospendere? 53
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B 53
Studio multicentrico, randomizzato per valutare l’efficacia e la sicurezza di un ciclo di monoterapia con Peg-Interferone alfa-2b della durata di 24 settimane verso un trattamento di 12 settimane di Peg-interferone alfa-2b in monoterapia o in associazione alla ribavirina in pazienti con epatite acuta C 53
Efficacia e tollerabilità a lungo termine della monoterapia con entecavir in pazienti con Epatite Cronica B 52
Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis 51
Genotypic resistance to adefovir (ADV) in patients with lamivudine (LAM) resistant chronic hepatitis B 51
ENTECAVIR FOR NUC-NAÏVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: LONG-TERM EFFECTIVENESS FROM A LARGE MULTICENTER COHORT STUDY IN 376 PATIENTS 51
Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir. 51
Lack of association between IL28B variants and HBsAg clearance after interferon treatment 50
Entecavir in “real-life”: risultati dello studio VIRGIL 50
HBV e migranti: risultati di uno studio multicentrico SIMIT 50
Entecavir effectiveness in naïve and NUC experienced patients: Interim analysis of the ENTAS cohort study of patients with chronic hepatitis B 50
Entecavir for NUC-naïve chronic hepatitis B patients in clinical practice: long-term effectiveness from large multicenter cohort study in 376 patients 49
ENTECAVIR EFFECTIVENESS IN DAILY CLINICAL PRACTICE, INTERIM ANALYSIS OF THE ITALIAN Master-Entas COHORT STUDY OF PATIENTS WITH CHRONIC HEPATITIS B 49
Reply. 48
Effectiveness and safety of therapy simplification from Lamivudine + Adefovir to Tenofovir monotherapy in virologically suppressed HBeAg-negative chronic hepatitis B patients 48
Epatiti virali croniche e gravidanza 48
Prediction of hepatocellular carcinoma in entecavir treated patients: results from 744 chronic hepatitis B patients in European Multicenter Study (VIRGIL) 47
Effectiveness and safety of tenofovir disoproxil fumarate in field practice: a multicenter European cohort study of 302 NUC-naïve patients with chronic hepatitis B 47
Effectiveness of entecavir for nuc-naive HBeAg-negative chronic hepatitis B patients in clinical practice: a 2-year multicenter cohort study in 311 patients 47
HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome 47
Efficacia e sicurezza della terapia a lungo termine con Entecavir (ETV) o Tenofovir (TDF) in pazienti con cirrosi epatica HBV correlata 46
La genetica dei virus epatitici: implicazioni cliniche e terapeutiche 45
I farmaci che bloccano l'entrata dell'HBsAg nell'epatocita: ruolo clinico 42
Totale 6.471
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.080
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.080
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020940 0 0 0 0 201 205 212 18 130 26 133 15
2020/2021917 127 2 105 8 109 9 121 21 119 118 28 150
2021/2022554 74 8 7 9 73 32 15 54 66 68 16 132
2022/20231.866 237 91 58 76 53 138 2 126 1.021 26 22 16
2023/2024196 37 10 7 13 20 43 26 8 3 3 1 25
2024/2025103 69 3 9 15 7 0 0 0 0 0 0 0
Totale 6.618